Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.05 · Revenue $43.64M · 5 analysts
Est. EPS $-0.04 · Revenue $50.66M · 4 analysts
Est. EPS $-0.10 · Revenue $211.58M · 5 analysts
Est. EPS $-0.00 · Revenue $66.77M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $185.7M | -28.3% | -21.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-130.8M | +9.7% | -232.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +18.0% | -57.0% | -21.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -3.6% | +96.0% | -880.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -70.4% | -26.0% | -325.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-70.7M | -218.7% | -14.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -38.1% | -344.7% | +9.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 16.8% | -85.5% | -32.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.60x | -12.4% | -31.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $770.6M | -23.6% | -15.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.91 vs -0.31 | -191.3% | -0.08 vs -0.04 | -83.8% |
| Revenue Surprise | $185.7M vs $184.9M | +0.4% | $51.4M vs $48.7M | +5.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Asarpota Rajesh | officer: Chief Financial Officer | Class A Common Stock | D | 5,465 | $7.68 |
| Aug 10, 2026 | Brust Bernd | director, officer: Chief Executive Officer | Class A Common Stock | D | 29,250 | $6.23 |
| Jul 30, 2026 | Asarpota Rajesh | officer: Chief Financial Officer | Class A Common Stock | D | 5,465 | $6.59 |
| Jul 8, 2026 | Brust Bernd | director, officer: Chief Executive Officer | Class A Common Stock | D | 29,250 | $5.92 |
| Jun 30, 2026 | Asarpota Rajesh | officer: Chief Financial Officer | Class A Common Stock | D | 65,584 | $6.39 |
Operator: Hello, and welcome, everyone, joining today's Maravai LifeSciences Q2 2026 Results Earnings Call. [Operator Instructions] Please note this call is being recorded. [Operator Instructions] It is now my pleasure to turn the meeting over to Deb Hart. Please go ahead. Debra Hart: Good afternoon, everyone. Thanks for joining us for our second quarter 2026 earnings call. The press release and slides accompanying today's call are available at investors.maravai.com. As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update; and our CFO, Raj Asorpota, will review our financial results. Dr. Chanfeng Zhao, our Chief Scientific Officer; and Kurt Oreshack, our Executive Vice President and General Counsel, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. Actual results could differ materially from expectations. We will undertake no obligation to update them. We refer you to Slide 3 for details on forward-looking statements and Slide 4 for our use of non-GAAP financial measures. The press release and the slides provide reconciliations to the most directly comparable GAAP measures, and we also post reconciling schedules to our investor website. Please also refer to Maravai's SEC filings for additional information on risks and uncertainties that may impact our operating results, performance and financial condition. Now I'll turn the call over to Bernd. Bernd Brust: Good afternoon, and thank you for joining us. We are very pleased with our second quarter performance, which builds on the strong momentum we established in the first quarter. Our results reflect solid execution across the business and reinforce our confidence in both our near-term outlook and long-term strategy. During the quarter, we generated revenue of $51.4 million, representing 9% year-over-year growth. TriLink revenue increased 12%, driven by strong demand for GMP consumables and continued strength in discovery mRNA, particularly from larger preclinical programs, building our potential GMP pipeline as customer programs advance into clinical development. Because TriLink supports customers throughout the drug development life cycle, we believe today's discovery success will create tomorrow's GMP opportunity. Cygnus also delivered another solid quarter with revenue growing 3% year-over-year, marking its fifth consecutive quarter of growth. Through its industry-leading HCP and ELISA portfolio, combined with expanding analytical services, Cygnus continues to provide stable, recurring, high-margin revenue while strengthening customer relationships across the biologics workflow. Our profitability improved significantly. Adjusted gross margin expanded more than 1,600 basis points year-over-year to 58.9%, while adjusted EBITDA improved by $19.1 million to $8.7 million. These results reflect higher revenue, a favorable product mix and the benefits of the …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Bernd Brust | Chief Executive Officer & Director | USD 1,287,356 | Male | 1967 | Active |
Rajesh J. Asorpota | Executive Vice President & Chief Financial Officer | USD 850,960 | Male | 1967 | Active |
Christine Dolan | Executive Vice President & GM of Cygnus Technologies | USD 803,309 | Female | 1968 | Active |
Kurt Oreshack | Executive Vice President, General Counsel & Secretary | USD 689,912 | Male | 1981 | Active |
Robert Andrew Eckert | Chairman of the Board | USD 175,000 | Male | 1962 | Active |
Judith A. Solecki | Senior VP & Chief Human Resources Officer | — | Female | — | Active |
Kate E. Broderick | Executive Vice President | — | — | — | Active |
Christopher Benoit | Executive Vice President & Advisor | — | Male | — | Active |
Chanfeng Zhao | Senior Vice President & Chief Scientific Officer | — | Female | — | Active |
Debra Hart | Senior Director of Investor Relations | — | Female | — | Active |
Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) by 64.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company's stock after buying an additional 558,050 shares during the
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares. Key Headlines Impacting Maravai LifeSciences Here are the key news stories impacting
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences (NASDAQ: MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CEO Bernd Brust said the performance extended momentum established in the first quarter, led by
Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
